Brand Reference: Mounjaro, Zepbound
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tirzepatide RxNorm Concept ID | 2601723 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $268.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1086.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $279.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $349.00 / mo | 38 Zero-PHI Verified Patient Logs |
C20 fatty-diacid-conjugated 39-amino-acid peptide acting as an imbalanced dual agonist at glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, driving synergistic first- and second-phase beta-cell insulin release, white adipose lipid buffering, and central caloric intake reduction.
Across 38 community cost disclosures for Tirzepatide (Mounjaro / Zepbound), cash buyers routing around $1086.00 retail markups capture a 68% discount ($349.00/mo benchmark vs $268.4500 NADAC acquisition).
Following administration (2.5 mg SC weekly), Tirzepatide achieves 80% subcutaneous bioavailability and 48 hours post-injection; 4 weeks steady state onset, governed by a ~120 hours (5 days) terminal half-life through endogenous peptide hydrolysis and fatty-acid beta-oxidation across liver/tissues.
Before initiating Tirzepatide at 2.5 mg SC weekly, clinical safety checklists rule out personal or family mtc; men 2 syndrome; history of necrotizing pancreatitis. Logged tolerability patterns center on mild nausea (26% of reports), constipation (18% of reports), fatigue (12% of reports).
Across 38 verified cash-pay logs, Tirzepatide achieves a 93.80% Worth-It rating with out-of-pocket spend averaging $349.00/mo versus $1086.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Local Pharmacy at 2.5 mg SC weekly for Tirzepatide; monthly out-of-pocket dropped to $307.12 compared with $1086.00 retail.
Completed 10 weeks on Tirzepatide (5.0 mg SC weekly). Zero notable side effects on steady dosing.
Consistent biomarker response on 7.5 mg SC weekly Tirzepatide sourced via Compounding ($404.84/mo cash pay without insurance prior authorization).